Lancet:放置心房分流器并不能减少心力衰竭事件发生率!

2022-02-03 Nebula MedSci原创

心房分流器的放置并没有减少心力衰竭事件的总发生率,也没有改善射血分数大于或等于40%的心力衰竭患者的健康状况

运动时,左心房压力负荷增加引发呼吸困难是射血分数保留或轻度降低的心力衰竭的标志。放置心房分流器可降低此类心衰患者运动时的肺毛细血管楔压。

该研究目的是评估心房内分流术是否可以减少这类患者的心衰事件或改善其健康状况。

这是一项随机、国际化、双盲、假-对照的临床使用,招募了年满40岁的有症状的心脏射血分数≥40%的心衰患者。随机1:1分成两组,接受放置心房分流器或假手术。主要终点是12个月时心血管死亡或非致死性缺血性卒中的分层复合、24个月内的总心衰发生率和12个月时堪萨斯城心肌病问卷总结评分的变化

主要疗效终点

2017年5月25日至2020年7月24日,共招募了1072位患者,其中626位被随机分到了心房分流器组(n=314)或假手术组(n=312)。两组的主要复合终点无明显差异(p=0.85),每个单终点也无组间差异。预定的亚组分析显示,心房分流器治疗对性别、右心房体积指数和运动20W水平时肺动脉收缩压不同的亚组有不同的治疗效果(男性、右心房体积指数≥29.7mL/m2和肺动脉收缩压>70mmHg的个体的预后均更差)。此外,两组间的复合安全性终点无明显差异。

详细的疗效终点

总之,心房分流器的放置并没有减少心力衰竭事件的总发生率,也没有改善射血分数大于或等于40%的心力衰竭患者的健康状况。

原始出处:

Sanjiv J Shah, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. The Lancet. February 01, 2022. https://doi.org/10.1016/S0140-6736(22)00016-2

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826770, encodeId=b8ae1826e7044, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Aug 03 06:04:42 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831457, encodeId=c8ec183145ee3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 19 23:04:42 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626976, encodeId=d58816269e60d, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sat Feb 05 08:04:42 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190080, encodeId=4634119008008, content=建议批准该口服抗病毒药物用于治疗不需, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Feb 04 08:24:56 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190051, encodeId=c31b1190051dc, content=讲得太好了,很喜欢这个软件, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8a56445009, createdName=是小迪呀, createdTime=Fri Feb 04 00:25:25 CST 2022, time=2022-02-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826770, encodeId=b8ae1826e7044, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Aug 03 06:04:42 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831457, encodeId=c8ec183145ee3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 19 23:04:42 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626976, encodeId=d58816269e60d, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sat Feb 05 08:04:42 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190080, encodeId=4634119008008, content=建议批准该口服抗病毒药物用于治疗不需, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Feb 04 08:24:56 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190051, encodeId=c31b1190051dc, content=讲得太好了,很喜欢这个软件, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8a56445009, createdName=是小迪呀, createdTime=Fri Feb 04 00:25:25 CST 2022, time=2022-02-04, status=1, ipAttribution=)]
    2022-08-19 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826770, encodeId=b8ae1826e7044, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Aug 03 06:04:42 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831457, encodeId=c8ec183145ee3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 19 23:04:42 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626976, encodeId=d58816269e60d, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sat Feb 05 08:04:42 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190080, encodeId=4634119008008, content=建议批准该口服抗病毒药物用于治疗不需, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Feb 04 08:24:56 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190051, encodeId=c31b1190051dc, content=讲得太好了,很喜欢这个软件, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8a56445009, createdName=是小迪呀, createdTime=Fri Feb 04 00:25:25 CST 2022, time=2022-02-04, status=1, ipAttribution=)]
    2022-02-05 sodoo
  4. [GetPortalCommentsPageByObjectIdResponse(id=1826770, encodeId=b8ae1826e7044, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Aug 03 06:04:42 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831457, encodeId=c8ec183145ee3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 19 23:04:42 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626976, encodeId=d58816269e60d, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sat Feb 05 08:04:42 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190080, encodeId=4634119008008, content=建议批准该口服抗病毒药物用于治疗不需, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Feb 04 08:24:56 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190051, encodeId=c31b1190051dc, content=讲得太好了,很喜欢这个软件, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8a56445009, createdName=是小迪呀, createdTime=Fri Feb 04 00:25:25 CST 2022, time=2022-02-04, status=1, ipAttribution=)]
    2022-02-04 查查佳佳

    建议批准该口服抗病毒药物用于治疗不需

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1826770, encodeId=b8ae1826e7044, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Aug 03 06:04:42 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831457, encodeId=c8ec183145ee3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 19 23:04:42 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626976, encodeId=d58816269e60d, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sat Feb 05 08:04:42 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190080, encodeId=4634119008008, content=建议批准该口服抗病毒药物用于治疗不需, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Feb 04 08:24:56 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190051, encodeId=c31b1190051dc, content=讲得太好了,很喜欢这个软件, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8a56445009, createdName=是小迪呀, createdTime=Fri Feb 04 00:25:25 CST 2022, time=2022-02-04, status=1, ipAttribution=)]
    2022-02-04 是小迪呀

    讲得太好了,很喜欢这个软件

    0

相关资讯

干货:急性左心衰竭的紧急处置

常见临床常见的急性左心衰竭干货内容,一文汇总

JAHA:老年人身体成分与心力衰竭的关系

总瘦体重与发生HF呈正相关,而总脂肪量和大腿肌肉密度与HF发生几率呈负相关。这些发现强调了DEXA在评估老年人HF风险的局限性,并支持计算机断层扫描测量的骨骼肌质量优于其重量作为HF发生的决定因素。

Heart:心肌病和心力衰竭的流行病学数据

所有记录的心肌病患病率在过去十年中都有所增加。CA的诊断通常早于心力衰竭,而ARVC或肥厚性心肌病的个体在其心肌病诊断后更容易发展为心力衰竭。

Eur J Heart Fail:高血浆GDF-15浓度心力衰竭患者相关的病理生理机制

患有HF和血浆较高GDF-15浓度患者的特征是炎症通路和与IGF-1调节和骨/组织重塑相关的通路显著激活。

BMJ:休克性院内心脏骤停患者除颤前慎用肾上腺素

在室性心律失常引起的院内心脏骤停患者救治过程中,近三成的患者违背现行指南,在除颤前进行了肾上腺素治疗,这与患者不良预后相关

Eur Heart J:利钠肽检测用于心力衰竭诊断的长期趋势

初级保健中对利钠肽进行检测随着时间的推移有所增加,没有明显不平等的证据,但大多数HF患者在诊断前仍然没有利钠肽的检测记录。